Abstract-Offspring of hypertensive pregnancies are at increased risk of developing hypertension in adulthood. In the neonatal period, they display endothelial cell dysfunction and altered microvascular development. MicroRNAs, as important endothelial cellular regulators, may play a role in this early endothelial dysfunction. Therefore, we identified differential microRNA patterns in endothelial cells from offspring of hypertensive pregnancies and determined their role in postnatal vascular cell function. Studies were performed on human umbilical vein endothelial cell samples from 57 pregnancies. Unbiased RNA sequencing identified 30 endothelial related microRNAs differentially expressed in human umbilical vein endothelial cells from hypertensive compared with normotensive pregnancies. Quantitative reverse transcription polymerase chain reaction confirmed a significant higher expression level of the top candidate, miR-146a. Combined miR-146a-targeted gene expression and pathway analysis revealed significant alterations in genes involved in inflammation, angiogenesis, and immune response in the same human umbilical vein endothelial cells. Elevated miR-146a expression level at birth identified cells with reduced ability for in vitro vascular tube formation, which was rescued by miR-146a inhibition. In contrast, miR-146a overexpression significantly reduced vascular tube formation in human umbilical vein endothelial cells from normotensive pregnancies. Finally, we confirmed that miR-146a levels at birth predicted in vivo microvascular development during the first 3 postnatal months. Offspring of hypertensive pregnancy have a distinct endothelial regulatory microRNA profile at birth, which is related to altered endothelial cell behavior and predicts patterns of microvascular development during the first 3 months of life. 
O ffspring of hypertensive pregnancies display changes in endothelial function from early in life 1 and are at an increased risk for hypertension in adulthood. [2] [3] [4] Circulating endothelial cells 5 and umbilical vein-derived endothelial cells 6 from neonates born to hypertensive pregnancies have altered cellular angiogenic capacity at birth. Furthermore, the poorer the function of the cells in vitro, the more likely the infant is to lose microvascular dermal density during the first postnatal months, as their circulation remodels. 6 Microvascular dermal rarefaction has been linked to higher blood pressure in young adults born to pregnancy complications, 7 and a primary abnormality in microvascular development presents a plausible mechanistic pathway to explain increased hypertensive risk for these offspring. 8 MicroRNAs are a class of noncoding RNAs that are important regulators of cellular function. 9 In recent years, several microRNAs have been shown to control aspects of endothelial cell behavior such as migration, proliferation, apoptosis, and vasculogenesis 10 with certain microRNAs identified to be proangiogenic and others antiangiogenic. [11] [12] [13] [14] [15] [16] [17] Previous studies have successfully demonstrated that alteration of endothelial microRNAs, using a knockdown approach, can have dramatic impacts on endothelial proliferation and tube formation in vitro. 13, 14 Stress conditions such as inflammation can also alter the regulation of microRNAs. 16 It is, thus, plausible that in utero stress exposure related to hypertensive pregnancies may program alterations in offspring microRNA profile. Therefore, we hypothesized that October 2018 endothelial cells from hypertensive pregnancy offspring would display a different pattern of microRNA expression compared with those derived from normotensive pregnancies. Furthermore, these patterns would predict vasculogenic capacity of endothelial cells and the in vivo development of the microvascular network in the neonate during the first 3 months of their postnatal life.
Methods

Study Cohort and Sample Collection
The data that support the findings of this study are available from the corresponding author on reasonable request. Mothers being cared for by Oxford University Hospitals NHS Foundation Trust between 2013 and 2015 were identified by their clinical care team and invited to take part in the Oxford Cardiovascular Tissue Bioresource program, coordinated by the Oxford Cardiovascular Clinical Research Facility and NHS Blood and Transplant. A clinical recruitment team approached mothers before delivery to seek consent for donation of tissue aiming for on average 2 to 3 participants every month. Mothers with either hypertensive or normotensive pregnancies were identified and approached in parallel to ensure balanced recruitment during a month. Rate of recruitment was controlled to ensure adequate time for sample preparation, including cord processing, cell isolation, and cell maintenance. Umbilical cords were collected immediately after delivery by a dedicated research cord collection team. All cords were processed within 12 hours of delivery. Human umbilical vein endothelial cells (HUVECs) were isolated and stored according to standard operating procedures (online-only Data Supplement). HUVECs were cultured in endothelial basal medium (EGM-2) supplemented with the EGM-2 bullet kit (catalog number: CC-3162; Lonza, UK). All cell cultures were maintained in humidified 5% CO 2 at 37°C. All RNA expression analyses were performed using cells from passage 1, whereas tube formation assays were performed with cells from passage 2 or 3.
Pregnancy history including blood pressure levels were recorded for each participant from maternity records. Hypertensive pregnancies, including pregnancy-induced hypertension and preeclampsia, were defined according to the International Society for the Study of Hypertension in Pregnancy guidelines (definitions are available in the online-only Data Supplement). Normotensive pregnancy was also confirmed from case records, and if there was subsequent evidence of problems during pregnancy such as fetal growth restriction or glucose intolerance, samples were not included in analysis. The measurement of microvascular measures at birth and 3 months of age in the infants has been reported previously 6 (detailed in online-only Data Supplement). All participants provided written consent with collection and subsequent experimental use of samples in accordance with approvals from appropriate National Research Ethics Committees (09/H0606/68, 07/H0606/148, 15/SC/0027, and 11/SC/0230).
RNA Sequencing
Total RNA (1-5 µg) isolated from HUVECs (n=8) was processed using the NEBNext Small RNA Library Prep Set for Illumina (catalog number: E7330L) according to manufacturer's recommendations. The microRNA component of the library was enriched and quantified by real-time quantitative polymerase chain reaction (PCR). Sequencing was performed as 50 bp single read on a GAIIx according to Illumina specifications using Cluster Generation Kit v4 and Sequencing Kit v4 (details are provided in the online-only Data Supplement). Quality control was performed to determine the proportion of reads mapping to genes and variation within the data set. The data were normalized using the R/BioConductor edgeR_2.99.0 package.
Reverse Transcription and PCR
TaqMan microRNA reverse transcription kit (Applied Biosystems; catalog number: 4366596) was used for cDNA synthesis according to the manufacturer's instructions. Expression of hsa-miR-146a in HUVECs was quantified using the microRNA TaqMan assay (Applied Biosystems; assay ID: 000468). Each PCR was performed in 3 technical replicates and expressed as fold change using the 2-ΔΔCt method. 18 Expression of miR-146a was normalized to the endogenous control RNU44 (Applied Biosystems; assay ID: 001094).
Gene Expression and Network Analysis
Total RNA of HUVECs was extracted using QIAGEN RNeasy Mini Kit (Qiagen, Germany) according to the manufacturer's instructions. RNA quality and abundance were assessed using a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies). Gene expression microarray analysis was conducted using Illunima HT-12v4 expression bead-chip arrays according to the manufacturer's protocol. The raw gene expression data were analyzed using the R/ BioConductor 'limma_3.26.9 package. Variance-stabilization and normalization algorithm was used for data normalization. Differential gene expression was determined using t tests/ANOVA.
Using the experimentally validated microRNA-target interactions database (miRTarBase; http://mirtarbase.mbc.nctu.edu.tw), the expression level of the microRNA-targeted genes was extracted from the gene expression array results. We conducted a network enrichment analysis using Metacore based on combination of the selected microRNA-targeted genes and the expression results from the array experiment. Statistical significance was corrected using Bonferroni adjustment for the total number of genes in each network.
Tube Formation and Cell Proliferation
Angiogenic capacity was assessed by performing tube formation using growth factor-reduced Matrigel (BD Biosciences, UK). Cell proliferation was assessed using the CyQUANT NF Cell Proliferation Kit (Life Technologies) according to the manufacturer's instruction (detailed in online-only Data Supplement).
Cell Transfection
HUVECs were plated in a 6-well plate at 1×10 5 cells per well overnight. Cells were transfected with hsa-miR-146a-5p mimic (10 nmol/L), or hsa-miR-146a-5p hairpin inhibitor (80 nmol/L), or respective nontargeting controls (control #1, Dharmacon) for 24 hours using Lipofectamine RNAiMAX (catalog number: 13778030; ThermoFisher) according to the manufacturer's instructions. Cells were then replaced with antibioticfree media for additional 48 hours and collected for functional assays. Transfections were visualized and optimized with fluorescently labeled mimic and inhibitor controls (Dharmacon). Transfection efficiency was >90%. The transfection of HUVECs with hsa-miR-146a inhibitor and mimic were confirmed by quantitative reverse transcription PCR, and immunoblotting was used to confirm alterations in a downstream protein level (details are provided in the online-only Data Supplement).
In Vivo Microvascular Imaging
Imaging of the axillary small vessel network was performed with Side Stream Dark Field imaging (Microscan; Microvision Medical, The Netherlands), as previously reported for neonates. 19 Measurements were performed after birth and again at 3 months, on the same side, in a temperature-controlled room, with the infant at rest, either in their mother's arms or in a crib (details are provided in the online-only Data Supplement).
Statistical Analysis
Statistical analyses were conducted using SPSS version 22 and GraphPad Prism 6.0. Comparisons between continuous variables were performed using a 2-tailed, independent samples t test for normally distributed variables and Mann-Whiney U test for nonnormally distributed data. Levels of variables across the distribution of non-normally distributed variables were analyzed with the cohort ranked into thirds or tenths of the distribution. Comparison of categorical variables was performed using a χ 2 test. Bivariable and multivariable regression models were performed using a forced entry method. Statistically significant variables from bivariable regression analysis were then included in a multivariable regression analysis. Pearson correlation was recorded for bivariable regression analysis. Standardized coefficients were used in the multiple regression analysis. Results are presented as mean±SD for normally distributed continuous variables, median (minimum-maximum) for non-normally distributed variables, and the number of observations (yes/no) with the percentage in each group for categorical variables. P values ≤0.05 were considered statistically significant.
Results
Cohort Characteristics
Samples from 57 pregnancies were used. Maternal and offspring demographic characteristics in the normotensive and hypertensive groups are presented in Table 1 . Normotensive and hypertensive pregnancy groups were matched for maternal age, with no differences in smoking and alcohol consumption at time of pregnancy. Maternal body mass index (BMI), proportion of cesarean section, and blood pressure during pregnancy were significantly higher in the hypertensive mothers. Infants in the hypertensive group were on average 2 weeks more premature with a lower birth weight z score. There were no differences in offspring sex distribution, head circumference, and Apgar score at 5 minutes between the 2 groups.
MicroRNA Profiles in HUVECs From Normotensive and Hypertensive Pregnancy Offspring
We selected 8 samples (4 hypertensive and 4 normotensive; Table S1 in the online-only Data Supplement), matched by maternal age and gestational age, based on a predefined RNA-sequencing experimental design for RNA-sequencing analysis with enrichment in microRNA profile to investigate the microRNA profile at birth. Thirty significantly altered microRNAs were identified between hypertensive and normotensive groups (P<0.05; Figure 1A ). On the basis of a literature review, 20 we identified 7 of these differentially expressed miRNAs (miR-146a, -27b, -31, -222 and -221, -130, and -92) in the hypertensive pregnancy cohort as having previously been reported to be regulators of endothelial responses (Table S2 ; Figure 1B ). After false-discovery rate adjustment (Bonferroni correction based on the 20 preselected microRNA targets), miR-146a remained significantly upregulated with a 2.39-fold higher level in hypertensive HUVECs compared with the normotensive samples. We, therefore, took miR-146a forward as a candidate microRNA for validation and downstream functional investigation.
Validation of MiR-146a in Hypertensive Pregnancy Offspring
We confirmed (using quantitative reverse transcription PCR) in the full cohort of 57 participants that the level of miR146a in hypertensive HUVECs was 1.74-fold higher than in the normotensive group (P=0.0006); miR-146a measured in a peripheral plasma sample was used as the reference sample for the comparison of hypertensive and normotensive samples ( Figure 1C ). We then studied other maternal and fetal risk factors that varied between hypertensive and normotensive pregnancy to determine whether there were any potential confounders in the association between hypertensive pregnancy and miR-146a fold change (Table S3) . In bivariable regression analysis, gestational age trended toward an inverse correlation with miR-146a (coefficient B=−0.24; P=0.08). Therefore, we included gestational age, along with hypertensive pregnancy and maternal age, as independent variables in a multivariable regression model. This analysis demonstrated that hypertensive pregnancy was an independent predictor of miR-146a level, with gestational age showing no association with miR-146a (coefficient B=0.01; P=0.96; Table 2 ).
MiR-146a-Targeted Pathway Analysis in Endothelial Cells From Hypertensive Pregnancy Offspring
To further determine the role of miR-146a to cellular function in endothelial cells from hypertensive pregnancies, we explored evidence of variation in the gene expression profile related to known targets for miR-146a using gene expression array data in the same cohort based on samples collected from 12 hypertensive and 12 normotensive mothers. After normalization, ANOVA comparative analysis identified 811 significantly differentially expressed genes (P<0.05). Because the aim of this analysis was to focus on miR-146a-targeted genes, we limited the investigation to 97 targets, which were previously validated and extracted from the miRTarBase database (http:// mirtarbase.mbc.nctu.edu.tw), with details in the Methods section. Among the 97 selected miR-146a gene targets, 67 targets were detected in the expression array results (Table S4) . Gene enrichment network analysis using Metacore was performed using the combined miR-146a-targeted gene list and gene expression profile. The combined approach has been shown to be instrumental in detecting group effects in microRNA expression and related target gene sets. 21 A summary of the miR-146a-targeted selection process is shown in Figure 2A . Using this selection process, 44 networks were identified with statistically significant associations (P<0.05) after correcting for the total number of genes in each pathway ( Figure S1 ). Among all miR-146a-targeted networks, the top 10 networks relate to inflammation, angiogenesis, and immune response ( Figure 2B ). Network objects are listed in Figure S2 showing the total number of networks that each object is involved in and ranking of each object among all network maps.
MiR-146a Regulates Endothelial Tube Formation in Offspring of Hypertensive Pregnancy
To establish whether manipulation of miR-146a level could directly influence the vascular phenotype of cells from offspring of hypertensive pregnancy, we transfected HUVECs derived from hypertensive and normotensive pregnancies with miR-146a mimic and hairpin inhibitor for 24 hours, with the average transfection efficiency greater than 90%. Subsequent quantitative reverse transcription PCR in HUVECs confirmed a significant increase in miR-146a level after transfection with miR-146a mimic (the effect of miR-146a mimic on a downstream target protein was confirmed by immunoblotting) and a 68% reduction in miR-146a after transfection with miR-146a hairpin inhibitor ( Figure S3) .
Functionally, overexpression of miR-146a reduced the total tubule length (17 627±958 versus 13 995±1295; P=0.05) and number of branching points (133±5 versus 100±11; P=0.03) in normal HUVECs, although similar responses were not apparent in already dysfunctional HUVECs derived from hypertensive pregnancies ( Figure 3A) . By contrast, inhibition of miR-146a restored the total tubule length (13 339±789 versus 16 064±644; P=0.04) and branching points (93±8 versus 128±3; P=0.008) in the hypertensive group only, indicating that inhibition of miR-146a in HUVECs derived from hypertensive pregnancy, to some extent, is capable of recovering angiogenic capacity compared with cells from the normotensive group. Indeed, tube formation was no longer significantly different between these 2 groups (P=0.26; Figure 3B ). Similar to the tube formation, overexpression of miR-146a in HUVECs from hypertensive pregnancies resulted in reduced cell proliferation that was ameliorated by miR-146a inhibition (66 593±4680 versus 80 970±5247; P=0.06; Figure 3 ).
Association of MiR-146a Expression With In Vitro and In Vivo Vessel Formation
To determine whether levels of miR-146a were relevant to the in vivo and in vitro microvascular responses observed in offspring born to hypertensive pregnancy, we correlated levels with endothelial capacity for tube formation and proliferation in 49 participants. The level of miR-146a expression was negatively associated with total tubule length (P=0.001), branch points (P=0.01), and cell proliferation (P=0.0; Figure 4A ; Figure S4 ). Further, there was a graded association between miR-146a levels and dermal microvascular density in the same individuals (10 hypertensive and 18 normotensive pregnancies) at 3 months postnatal age ( Figure 4B) , with higher miR-146a levels related to reduced microvascular density at 3 months (P=0.003 for total vessel density; P=0.005 for De Backer score).
Discussion
Our study shows that endothelial cells from neonates born after a hypertensive pregnancy have significantly altered expression levels of microRNAs compared with equivalent cells from offspring of normotensive pregnancies. Specific microRNAs known to be relevant to endothelial cell phenotype/function, and, in particular, miR-146a, differ significantly in endothelium of hypertensive pregnancy offspring, with associated changes in the expression level of their gene targets. These differences in the microRNA profile are also associated with an impaired in vitro endothelial cell tubulogenesis phenotype in offspring of hypertensive pregnancies, which can be induced by miR-146a overexpression and rescued by miR-146a inhibition. Finally, we demonstrate that microRNA expression profile at birth in the HUVECs of an offspring can predict the pattern of microvascular development in that neonate during the next 3 months of life. Although the molecular mechanism through which miR-146a modulates vasculogenesis has not been explored, these results support a regulatory role of microRNAs in endothelial dysfunction seen in offspring of hypertensive pregnancy.
The early postnatal period is considered a critical developmental window for the microvasculature. Our previous work demonstrated that endothelial cellular behavior at birth predicts early postnatal microvascular remodeling. 6 Posttranscriptional regulation of gene expression by microRNAs is known to be important to several endothelial phenotypes, 20 and, therefore, we were able to increase the efficiency of our study by using prior knowledge from the literature to focus on candidate endothelial microRNAs. A drawback of this approach is that it did not allow us to probe for potentially relevant novel microRNA targets. Nevertheless, the 7 validated microRNAs have previously been linked with changes in angiogenesis and endothelial cell tubulogenesis and were confirmed in our study. 11, [13] [14] [15] [16] [17] 22 Our findings are, therefore, consistent with previous evidence for these microRNAs and, for the first time, implicates them as mediators of the antiangiogenic state previously reported in endothelial colony-forming cells 5, 23 and umbilical-derived endothelial cells 6 collected in neonates born after a hypertensive pregnancy.
The greatest difference in microRNA expression levels was for miR-146a, a microRNA that has previously been studied in relation to angiogenesis in cancer, 24, 25 innate immune signaling, 12, 26 and inflammatory pathways. 22, 27 MiR146a is upregulated, as part of a feedback loop, on activation of a proinflammatory transcriptional program related to NF-kB (nuclear factor κ-light-chain-enhancer of activated B cells) signaling. 26, 28 After removal of proinflammatory cytokines, elevated levels of miR-146a are sustained for several days, suggesting the maintenance of a prolonged inflammatory memory. 22 Using gene expression profiling in endothelial cells from normal and hypertensive offspring, we confirmed variation in miR-146a target pathways related to inflammation. Severe hypertensive pregnancies, such as preeclampsia, commonly induce a proinflammatory state in the mother. 29 It is, therefore, plausible that the elevated levels of miR-146a levels in the neonate reflect a persistent upregulation after exposure of the fetus to an inflammatory insult during pregnancy. However, other studies suggest that the fetus is relatively protected from the adverse maternal circulating milieu, 30 except in the most severe pregnancy complications with associated fetal growth restriction. This was not a predominant finding in our participant population, and we found miR-146a to have antiangiogenic properties, in contrast to the proangiogenic miR146a response seen during inflammation. 25 HUVECs exposed to a major inflammatory insult such as lipopolysaccharide 29 or when grown in an adverse metabolic state, such as seen in diabetes mellitus, 28 can be induced to increase miR-146a expression and enhance their tubule formation.
Our cells were maintained in a neutral environment, and differences in miR-146a were already evident at baseline. Endothelial colony-forming cells from patients with coronary artery disease similarly have increased levels of miR-146a and exhibit reduced angiogenic capacity. 31 Consistent with our observations, inhibition of miR-146a restores endothelial tubulogenesis in endothelial colony-forming cells from patients with coronary artery disease, via a distinct RhoJdependent mechanism.
31 miR-146a also inhibits neoformation of blood vessels in a model of choroidal lesions, and blocking miR-146a leads to longer tube formation in an ex vivo aortic ring angiogenic assay.
14 An equivalent, antiangiogenic impact of miR-146a has been associated with other pregnancy complications. 14 Halkein et al 14 showed that exosomal miR146a levels are increased in peripartum cardiomyopathy, and myocardial uptake results in apoptosis and reduced angiogenesis. Furthermore, overexpression of miR-146a was found to repress proliferation and apoptosis in vitro.
We grouped results from offspring born to both pregnancy-induced hypertension and preeclampsia as we have previously shown these pregnancy complications are both associated with differences in endothelial cell behavior in the neonates. 6 However, the sample size was not sufficient to determine whether there are graded effects between offspring born to these 2 distinct hypertensive pregnancy complications. Maternal miR-146a levels are also altered during pregnancy, in a dose-dependent manner, in response to tobacco smoke exposure. 32, 33 Therefore, we undertook a regression analysis to understand whether other pregnancy factors such as maternal BMI or fetal factors such as gestational age or growth restriction may be confounders for the association we found between hypertensive pregnancy and offspring endothelial microRNA levels. This indicated that the main predictor of miR-146a levels in the neonate was a history of hypertensive pregnancy rather than other factors such as preterm birth. Small group differences in maternal BMI were evident, both in the smaller RNA-sequencing cohort and full cohort. However, we found no relationship between maternal BMI and miR-146a levels in our cohort, suggesting the relationship between hypertensive pregnancies and miR-146a in the offspring is independent of maternal BMI. Nevertheless, we did not have information on some factors such as maternal metabolic function, and given the differences in maternal BMI between study groups, future studies will be needed to assess how metabolic alterations and lifestyle alter miR-146a level. It has recently been suggested that offspring born to normotensive pregnancies, but whose mother has a history of hypertensive pregnancy, may also be predisposed to hypertension 34 ; thus, it will be interesting to see whether altered microRNA profiles are seen in circulating endothelial cells at other points in life or in siblings of affected families. Future studies will then be able to assess the relative contribution of family history of hypertension to these alterations in endothelial phenotype in the offspring.
Expression array analysis was performed in cells at passage 1, whereas in vitro tube formation assays were performed with cells from passage 2 or 3. It has previously been shown that there is a slight shift in microRNA expression from passage 1 to 2 or 3, 35 and, therefore, this may have weakened any association between expression levels and the in vitro assay. Furthermore, microRNA-146a levels were validated using the ΔΔCt method for quantification, which makes several assumptions that are addressed using other approaches such as Cq quantification. 36 Nevertheless, multiple quality control steps were taken to ensure high-quality PCR, and we showed rescue of vasculogenic potential by inhibition of miR-146a. It will be of interest to explore in experimental models whether miR-146a can also alter postnatal microvascular development in vivo. Our data in humans are necessarily associative, and we cannot prove causality for associations between endothelial capacity and microvascular remodeling. However, the graded nature of the association suggests that the endothelial cell phenotype is a biomarker at birth that usefully predicts patterns of vascular development. It is possible that manipulation of microRNA profile during a critical postnatal window of development could have longterm benefits for vascular development and, hence, alter risk for later development of hypertension. Because microRNAs tend to have multiple gene targets and are interdependent, it is possible that the effects on tubulogenesis involve multiple pathways that can be targeted distinctly, and experimental models will be of value to explore molecular signals.
Perspectives
This study has shown for the first time that endothelial cells from neonates born after a hypertensive pregnancy have a distinct microRNA profile associated with an altered endothelial phenotype. The most upregulated microRNA was miR-146a, and its levels predict both in vivo and in vitro vascular phenotypes seen in hypertensive pregnancy offspring. Furthermore, inhibition of miR-146a resulted in rescue of the antiangiogenic state. These results suggest that microRNAs are central to the abnormal vascular state observed in offspring of hypertensive pregnancy.
